Anti-GP1BB/ BDPLT1/ BS monoclonal antibody
Anti-GP1BB/ BDPLT1/ BS antibody for FACS & in-vivo assay
Go to GP1BB/GP1BB products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP0486-Ab-1/ GM-Tg-hg-MP0486-Ab-2 | Anti-Human GP1BB monoclonal antibody | Human |
GM-Tg-rg-MP0486-Ab-1/ GM-Tg-rg-MP0486-Ab-2 | Anti-Rat GP1BB monoclonal antibody | Rat |
GM-Tg-mg-MP0486-Ab-1/ GM-Tg-mg-MP0486-Ab-2 | Anti-Mouse GP1BB monoclonal antibody | Mouse |
GM-Tg-cynog-MP0486-Ab-1/ GM-Tg-cynog-MP0486-Ab-2 | Anti-Cynomolgus/ Rhesus macaque GP1BB monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP0486-Ab-1/ GM-Tg-felg-MP0486-Ab-2 | Anti-Feline GP1BB monoclonal antibody | Feline |
GM-Tg-cang-MP0486-Ab-1/ GM-Tg-cang-MP0486-Ab-2 | Anti-Canine GP1BB monoclonal antibody | Canine |
GM-Tg-bovg-MP0486-Ab-1/ GM-Tg-bovg-MP0486-Ab-2 | Anti-Bovine GP1BB monoclonal antibody | Bovine |
GM-Tg-equg-MP0486-Ab-1/ GM-Tg-equg-MP0486-Ab-2 | Anti-Equine GP1BB monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP0486-Ab-1/ GM-Tg-hg-MP0486-Ab-2; GM-Tg-rg-MP0486-Ab-1/ GM-Tg-rg-MP0486-Ab-2; GM-Tg-mg-MP0486-Ab-1/ GM-Tg-mg-MP0486-Ab-2; GM-Tg-cynog-MP0486-Ab-1/ GM-Tg-cynog-MP0486-Ab-2; GM-Tg-felg-MP0486-Ab-1/ GM-Tg-felg-MP0486-Ab-2; GM-Tg-cang-MP0486-Ab-1/ GM-Tg-cang-MP0486-Ab-2; GM-Tg-bovg-MP0486-Ab-1/ GM-Tg-bovg-MP0486-Ab-2; GM-Tg-equg-MP0486-Ab-1/ GM-Tg-equg-MP0486-Ab-2 |
Products Name | Anti-GP1BB monoclonal antibody |
Format | mab |
Target Name | GP1BB |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-GP1BB benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species GP1BB/ BDPLT1/ BS VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLP004607 | human GP1BB Lentivirus plasmid |
ORF Viral Vector | vGMLP004607 | human GP1BB Lentivirus particle |
ORF Viral Vector | pGMLPm004622 | mouse Gp1bb Lentivirus plasmid |
ORF Viral Vector | vGMLPm004622 | mouse Gp1bb Lentivirus particle |
Target information
Target ID | GM-MP0486 |
Target Name | GP1BB |
Gene ID | 2812,14724,116727,712129,100298963,111774801 |
Gene Symbol and Synonyms | BDPLT1,BS,CD42C,GP1BB,GPIBB,GPIbbeta |
Uniprot Accession | P13224,Q9JJM7 |
Uniprot Entry Name | GP1BB_HUMAN,GP1BB_RAT |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000203618 |
Target Classification | N/A |
The target: GP1BB, gene name: GP1BB, also named as BDPLT1, BS, CD42C, GPIBB, GPIbbeta. Platelet glycoprotein Ib (GPIb) is a heterodimeric transmembrane protein consisting of a disulfide-linked 140 kD alpha chain and 22 kD beta chain. It is part of the GPIb-V-IX system that constitutes the receptor for von Willebrand factor (VWF), and mediates platelet adhesion in the arterial circulation. GPIb alpha chain provides the VWF binding site, and GPIb beta contributes to surface expression of the receptor and participates in transmembrane signaling through phosphorylation of its intracellular domain. Mutations in the GPIb beta subunit have been associated with Bernard-Soulier syndrome, velocardiofacial syndrome and giant platelet disorder. The 206 amino acid precursor of GPIb beta is synthesized from a 1.0 kb mRNA expressed in plateletes and megakaryocytes. A 411 amino acid protein arising from a longer, unspliced transcript in endothelial cells has been described; however, the authenticity of this product has been questioned. Yet another less abundant GPIb beta mRNA species of 3.5 kb, expressed in nonhematopoietic tissues such as endothelium, brain and heart, was shown to result from inefficient usage of a non-consensus polyA signal in the neighboring upstream gene (SEPT5, septin 5). In the absence of polyadenylation from its own imperfect site, the SEPT5 gene produces read-through transcripts that use the consensus polyA signal of this gene. [provided by RefSeq, Dec 2010].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.